While the current pandemic of coronavirus disease 2019 (COVID-19) has largely spared children from severe illness, relative to adults, its causative pathogen – the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – can still cause infection and post-acute sequelae in…
Read More
World Health Organization simplifies names of SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread globally, infecting over 172 million people, and claiming the lives of more than 3.7 million individuals. During the past few months, new variants of concerns have emerged and come to…
Read More
STING agonist diABZI shows promise against SARS-CoV-2 variants
COVID-19 vaccines are the most effective way to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. For people who are already infected, new research suggests the small molecule stimulator of interferon genes (STING) agonist-1, diABZI, may be effective in…
Read More
Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines
Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019…
Read More
Can biomaterials offer novel therapeutic strategies against COVID-19?
The global coronavirus disease 2019 (COVID-19) pandemic rages on. To date, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has infected over 138.3 million and caused over 2.9 million deaths the world over. Despite major gains…
Read More
Experimental evidence that ADAM17 inhibition prevents severe COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that is contagious in humans. It is the causal agent of the ongoing coronavirus 2019 (COVID-19) pandemic. This virus causes a mild to severe infection and has…
Read More
Researchers identify SARS-CoV-2 antiviral compounds using protein assay
On March 11, 2020, the World Health Organization (WHO) announced the coronavirus disease 2019 (COVID-19) to be a pandemic. COVID-19 is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen, which is deemed to be highly contagious…
Read More
Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape
The current pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered an intensive hunt for effective new and repurposed antivirals and antibodies, for prevention and treatment of the infection. A new preprint…
Read More
Researchers explore an inhalable SARS-CoV-2 nanobody therapy
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the world’s third major coronavirus outbreak. To date, the SARS-CoV-2 has infected over 135 million lives and caused over 2.9 million deaths. Even…
Read More
Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants
A new monoclonal antibody targets a particular region of the receptor-binding domain (RBD) on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This region is usually not accessible to immune cells, which may be why it has broad neutralizing capabilities….
Read More